Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer

Zhang, Panpan; Su, Tong; Zhang, Shu

doi:10.1155/2021/5574176

Cited by 8 publications

(6 citation statements)

References 35 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…63 LAMTOR2 has strong interaction with the expression of the MEX3A, which owns prognostic value in ovarian cancer. 64 With the help of the signature, each LGG sample could be identified by its own risk level. In addition, we found that high-risk LGG patients had poor prognosis, upregulated infiltration of neutrophil, macrophage (M1 and M2), Treg, and myeloid dendritic cell, downregulated infiltration of monocyte and NK cell, and increased expression of large number of ICG genes.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analyses and experimental validation of the role of phagocytosis in low‐grade glioma

Fei,

Lu,

Feng

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundPhagocytosis is of vital importance in tumor immune response. The alteration of phagocytosis in low‐grade glioma (LGG) has not been investigated.MethodsThe mRNA, copy number variation, single nucleotide variation, and methylation levels of phagocytosis‐related genes were summarized in pan‐cancer. Non‐negative matrix factorization clustering was utilized to identify two LGG subtypes. LASSO regression analysis was performed to construct a phagocytosis‐related prognostic signature (PRPS). Immune characteristics, immunotherapy response, and targeted‐drug sensitivity were further explored. The phagocytosis activity in glioma was evaluated using scRNA‐seq data. Multiplex immunohistochemical (m‐IHC) technology was performed to identify the tumor‐infiltrating immune cells in LGG.ResultsThe phagocytosis‐related genes altered obviously in pan‐cancer compared with corresponding normal tissues. Two LGG subtypes were obtained and the subtype with poor prognosis was combined with lower tumor purity, more active immune‐related pathways, increasing infiltration of CD4+ T cells, CD8+ T cells, and natural killer (NK) cells, decreasing infiltration of macrophages, mast cells, and neutrophils, distinct pathway activity and cell death status, greater response to immunotherapy, and higher sensitivity to cyclophosphamide, erlotinib, gefitinib, lapatinib, and sorafenib. In addition, a PRPS involving 10 genes (i.e., SLC11A1, CAMK1D, PLA2G5, STAP1, ALOX15, PLCG2, SFTPD, AZU1, RAB27A, and LAMTOR2) was constructed to estimate the risk level of each LGG sample and high risk LGG patients had poor prognosis, upregulated infiltration of neutrophil, macrophage, Treg, and myeloid dendritic cell, down regulated infiltration of monocyte and NK cell, and increasing expression of large number of immune checkpoint genes. The phagocytosis activity is notably active in monocyte/macrophage. The m‐IHC results confirmed increased infiltration of macrophages and neutrophils in LGG samples with high SLC11A1 expression.ConclusionThe molecular characteristics of phagocytosis were revealed and the PRPS laid the foundation for personalized therapy in LGG.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics analyses and experimental validation of the role of phagocytosis in low‐grade glioma

Fei,

Lu,

Feng

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…Recent research shows that MEX3A is highly expressed in a variety of cancers and promotes the occurrence and metastasis of cancer, which is related to the poor prognosis of patients [ 27 – 29 ]. MEX3A might regulate immune infiltration in the microenvironment of ovarian cancer cells and is a potential therapeutic target [ 30 ]. However, MEX3A was reported to suppress proliferation and EMT by restraining the Akt signaling pathway in cervical cancer [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS

Zhao

Diao

et al. 2022

Cell Death Dis

View full text Add to dashboard Cite

The latest research shows that RNA-binding proteins (RBPs) could serve as novel potential targets for cancer therapy. We used bioinformatics analysis to screen and identify the key RBPs in ovarian cancer, from which we found that Mex-3 RNA Binding Family Member A (MEX3A) was intimately associated with the clinical prognosis of ovarian cancer. Nevertheless, little is known about its biological roles in ovarian cancer. In this case, we observed that MEX3A was highly overexpressed in fresh-frozen ovarian cancer tissues. MEX3A knockdown suppressed the development and invasion of ovarian cancer cells, while MEX3A overexpression promoted the proliferation and invasion of ovarian cancer cells. Mechanistically, TIMELESS was the critical downstream target gene of MEX3A, as demonstrated through alternative splicing event analysis based on RNA-seq. MEX3A knockdown resulted in retention of intron twenty-three of TIMELESS mRNA and decreased TIMELESS mRNA owing to stimulation of nonsense-mediated RNA decay (NMD). Additionally, we found that TIMELESS overexpression with MEX3A knockdown partially restored the proliferation ability of ovarian cancer cells. The results of this paper demonstrated that the MEX3A/TIMELESS signaling pathway was a key regulator of ovarian cancer, and MEX3A was a novel possible treatment target for ovarian cancer patients.

show abstract

“…Because SMYD2 usually upregulates gene expression by mediating the H3K36 methylation, we therefore, explored genes showing positive correlation with SMYD2 and obtained that SMYD2 activated MEX3A expression by promoting H3K36me2 modification on its promoter. MEX3A has been reported as a tumour promoter in several human cancers, [35][36][37][38] or as a tumour suppressor in cervical cancer. 39 The different roles might be owing to the different targets it affects.…”

Section: Discussionmentioning

confidence: 99%

SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth

Pan

Fan

Zhou

2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Dysfunction of the protein methyltransferase SET and MYND domain-containing protein 2 (SMYD2) is frequently linked to multiple diseases including cancer. The study focused on the role of SMYD2 in colorectal cancer (CRC) development.SMYD2 was expressed at high levels in CRC tissues and cells. Knockdown of SMYD2 in LOVO cells reduced cell proliferation, migration and invasiveness in vitro and it suppressed xenograft tumorigenesis in vivo. Overexpression of SMYD2 in HCT116 cells led to inverse trends. Mex-3 RNA binding family member A (MEX3A) was predicted as a target of SMYD2. Chromatin immunoprecipitation (ChIP)-reverse transcription quantitative polymerase chain reaction (qPCR) and cellular assays were performed and validated that SMYD2 activated MEX3A expression by promoting H3K36me2 modification on its promoter. Data in the STRING bioinformatics system indicated caudal type homeobox 2 (CDX2) as an important MEX3A-related gene.Silencing of MEX3A alone blocked proliferation and growth of CRC cells in vitro and in vivo, whereas MEX3A overexpression promoted cell growth by suppressing CDX2.In rescue experiments, MEX3A silencing suppressed the cell growth augmented by SMYD2, and CDX2 downregulation restored the malignance of cancer cells inhibited by MEX3A silencing. Taken together, this study reports that SMYD2-mediated activation of MEX3A augments progression of CRC by suppressing CDX2.

show abstract

Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer

Cited by 8 publications

References 35 publications

Bioinformatics analyses and experimental validation of the role of phagocytosis in low‐grade glioma

Bioinformatics analyses and experimental validation of the role of phagocytosis in low‐grade glioma

MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS

SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth

Contact Info

Product

Resources

About